COMORBIDITY OF PATIENTS WITH FIBROMYALGIA SYNDROME

Abstract

The representation of primary fibromyalgia (PFM) is 4% in the general population and 6-10% [10] in general clinical practice, PFM can be observed at any age, but the period from 25 to 45 years is predominant, which is estimated as the most able-bodied [5, 13]. Currently, PFM is considered an independent disease, which is reflected in the diagnostic criteria of ACR (1990 ) [2, 6]. However, the etiology and pathogenesis of PFM are still debatable [12]. Violations of the central mechanisms of pain regulation are of great importance [1, 7]. Sensory dysfunction was revealed, which manifests itself in an exacerbated perception of pain [11]. The combination of pain with sleep disturbance, anxiety, depression, and the effectiveness of antidepressants also support this position [3,4, 14 ]. The study of the state of the autonomic nervous system in this pathology revealed the presence of suprasegmental disorders that are characterized by polysystem [8, 15]. At the II Congress of the European Federation for the Study of Pain (1997), PFM was considered as a model of dysfunction of nociceptive systems [9, 11]. High resistance to therapy is one of the leading factors that make PFM treatment an extremely urgent problem in medicine.